The Zhitong Finance App learned that Jinxin Reproduction (01951) rose more than 8%. As of press release, it had risen 8.25% to HK$3.28, with a turnover of HK$151 million.

According to the news, the Jiangxi Provincial Medical Security Bureau recently issued the “Jiangxi Provincial Basic Medical Insurance Medical Service Project Payment Management Catalogue (2024)”. According to this catalogue, nine assisted reproduction programs, including “egg retrieval” and “artificial insemination,” are included in the scope of medical insurance payments in Jiangxi Province. The policy will be officially implemented from June 1, 2024. Also, starting in June, Chengdu will comprehensively improve medical treatment for maternity. Haitong International previously stated that China's assisted reproduction market has broad prospects. With the increase in the number of elderly mothers in China and the gradual advancement of measures such as active childbearing encouragement policies and inclusion in health insurance, the boom in China's ARS industry is expected to pick up.

Furthermore, the Health and Health Commission held a press conference on May 9 to highlight the latest developments and specific measures to “implement the requirements for high-quality population development and actively establish a fertility support policy system”. Huafu Securities said that the market has responded positively to this, especially the infant and assisted reproduction related concept sector. With the emphasis placed on building a childbirth-friendly society at the national level, enterprises in these fields are viewed as direct beneficiaries, and future development prospects are generally promising.